Search

Your search keyword '"García-Merino, Juan A"' showing total 91 results

Search Constraints

Start Over You searched for: Author "García-Merino, Juan A" Remove constraint Author: "García-Merino, Juan A"
91 results on '"García-Merino, Juan A"'

Search Results

1. Exome sequencing study in patients with multiple sclerosis reveals variants associated with disease course

2. CSF Chitinase 3–Like 2 Is Associated With Long-term Disability Progression in Patients With Progressive Multiple Sclerosis

3. Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes

4. Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab

5. The Multiple Sclerosis Data Alliance Catalogue

6. The eSports in the Spanish radio

8. New Algorithms Improving PML Risk Stratification in MS Patients Treated With Natalizumab

10. New Algorithms Improving PML Risk Stratification in MS Patients Treated With Natalizumab

11. Clinical characteristics and impact on patient-reported outcomes and quality of life of people with ambulatory secondary progressive multiple sclerosis: DISCOVER study

12. XII Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2019 (I)

13. Exome sequencing study in patients with multiple sclerosis reveals variants associated with disease course

14. Additional file 1: of Exome sequencing study in patients with multiple sclerosis reveals variants associated with disease course

15. Revisión de las novedades presentadas en el Congreso ECTRIMS 2018: XI Reunión Post-ECTRIMS (II)

17. Exome sequencing study in patients with multiple sclerosis reveals variants associated with disease course

18. Revisión de las novedades del Congreso ECTRIMS 2017, presentadas en la X Reunión Post-ECTRIMS (II)

19. Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes

20. Pharmacogenomic study in patients with multiple sclerosis

21. Revisión de las novedades del XXXII Congreso ECTRIMS 2016, presentadas en la IX Reunión Post-ECTRIMS (I)

22. Revisión de las novedades presentadas en el XXVII Congreso del Comité Europeo para el Tratamiento e Investigación en Esclerosis Múltiple (ECTRIMS) (I)

23. Revisión de las novedades del XXXI Congreso ECTRIMS 2015, presentadas en la VIII Reunión Post-ECTRIMS

24. Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab

25. Pharmacogenomic study in patients with multiple sclerosis

26. Revisión de las novedades del congreso conjunto ECTRIMS-ACTRIMS 2014, presentadas en la VII Reunión Post-ECTRIMS (I)

28. The cannabinoid system in human mesenchymal cells

29. Revisión de las novedades presentadas en el XXIX Congreso del Comité Europeo para el Tratamiento e Investigación en Esclerosis Múltiple (ECTRIMS) (I)

30. Guillain-Barré syndrome following the 2009 pandemic monovalent and seasonal trivalent influenza vaccination campaigns in Spain from 2009 to 2011: outcomes from active surveillance by a neurologist network, and records from a country-wide hospital discharge database.

31. Revisión de las novedades presentadas en el XXVIII Congreso del Comité Europeo para el Tratamiento e Investigación en Esclerosis Múltiple (ECTRIMS) (II)

32. Biomarcadores en esclerosis múltiple

33. Revisión de las novedades presentadas en el XXVII Congreso del Comité Europeo para el Tratamiento e Investigación en Esclerosis Múltiple (ECTRIMS) (II)

35. Revisión de las novedades presentadas en el XXVI Congreso del Comité Europeo para el Tratamiento e Investigación en Esclerosis Múltiple (ECTRIMS) (I)

38. El interferón beta natural en el tratamiento de la esclerosis múltiple recurrente­remitente: un ensayo clínico de fase II, multicéntrico, aleatorizado y controlado por RMN

39. Tratamiento actual de la esclerosis múltiple con interferón beta

40. Guillain-Barré syndrome following the 2009 pandemic monovalent and seasonal trivalent influenza vaccination campaigns in Spain from 2009 to 2011: outcomes from active surveillance by a neurologist network, and records from a country-wide hospital discharge database

41. Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes

42. Células mesenquimales y encefalomielitis autoinmune experimental : patrones de circulación celular y efecto del cannabidiol

43. Características fenotípicas y funcionales de las células mesenquimales multipotenciales del estroma de médula ósea en la esclerosis múltiple. Efecto de la encefalomielitis autoinmune experimental e implicación del sistema cannabinoide

44. The Multiple Sclerosis Data Alliance Catalogue Enabling Web-Based Discovery of Metadata from Real-World Multiple Sclerosis Data Sources

45. Inmunofenotipo y perfil transcriptómico de pacientes con esclerosis múltiple tratados con fingolimod. Diseño de un modelo de predicción de respuesta. Estudio traslacional a 2 años

46. Estudio del tratamiento con un cannabinoide sintético, WIN 55, 212-2, en la encefalomielitis autoinmune experimental, modelo animal de esclerosis múltiple: análisis del receptor de cannabinoides CB2 en pacientes

47. Three-Year Effectiveness of Dimethyl Fumarate in Multiple Sclerosis: A Prospective Multicenter Real-World Study.

48. Review of the novelties presented at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (III).

49. Review of the novelties presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (III).

50. [Biomarkers in multiple sclerosis].

Catalog

Books, media, physical & digital resources